|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10361037103810391040104110421043104410451046...10631064» |
- ||||| dexamethasone / Generic mfg.
Trial initiation date: TRARO (Traumeel® S in Rotator Cuff Syndrome)-Study (clinicaltrials.gov) - Jun 13, 2013
P3, N=160, Recruiting, Sponsor: Biologische Heilmittel Heel GmbH
Initiation date: Dec 2012 --> Apr 2013
- GCS 100 IV / Innoviva
Enrollment change, Combination therapy: GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jun 13, 2013
P1/2, N=0, Withdrawn, Sponsor: La Jolla Pharmaceutical Company
Initiation date: Dec 2012 --> Apr 2013 N=18 --> 0
- GCS 100 IV / Innoviva
Enrollment change: Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2013
P1/2, N=9, Terminated, Sponsor: La Jolla Pharmaceutical Company
N=18 --> 0 N=40 --> 9
- dinaciclib (MK-7965) / Merck (MSD)
Enrollment open, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Jun 13, 2013
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 9 Not yet recruiting --> Recruiting
- |||||| dexamethasone / Generic mfg.
Enrollment open: TRARO (Traumeel® S in Rotator Cuff Syndrome)-Study (clinicaltrials.gov) - Jun 13, 2013
P3, N=160, Recruiting, Sponsor: Biologische Heilmittel Heel GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| AZD5423 / AstraZeneca
Trial completion: Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol (clinicaltrials.gov) - Jun 13, 2013
P2, N=353, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Metastases: S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 11, 2013
P2, N=34, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=55 --> 34
- Enrollment change: S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 11, 2013
P2, N=147, Active, not recruiting, Sponsor: Southwest Oncology Group
N=55 --> 34 N=99 --> 147
- montelukast / Generic mfg., fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Enrollment open: SAPS: A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial (clinicaltrials.gov) - Jun 10, 2013
P4, N=20, Recruiting, Sponsor: University of California, San Diego
N=99 --> 147 Not yet recruiting --> Recruiting
- | dexamethasone / Generic mfg., ondansetron / Generic mfg.
New P4 trial, Surgery, Bariatric surgery: Dexamethasone and Ondansetron Versus Placebo for Postoperative Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P4, N=120, Recruiting, Sponsor: Hopital Foch
- ||||| cyclophosphamide / Generic mfg.
Enrollment closed: Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma (clinicaltrials.gov) - Jun 10, 2013
P3, N=53, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | prednisone / Generic mfg.
Trial completion: Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 10, 2013
P3, N=392, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | New P4 trial: Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee (clinicaltrials.gov) - Jun 9, 2013
P4, N=100, Completed, Sponsor: Thammasat University
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene (clinicaltrials.gov) - Jun 9, 2013
P1/2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Enrollment change: Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 9, 2013
P3, N=287, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=400 --> 287
- ||| TOL101 / Tolera Therap
Enrollment closed: Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection (clinicaltrials.gov) - Jun 9, 2013
P1/2, N=85, Active, not recruiting, Sponsor: Tolera Therapeutics, Inc
N=400 --> 287 Recruiting --> Active, not recruiting
- dexamethasone / Generic mfg., ondansetron / Generic mfg.
Enrollment open, Surgery, Bariatric surgery: Dexamethasone and Ondansetron Versus Placebo for Postoperative Nausea and Vomiting (clinicaltrials.gov) - Jun 8, 2013
P4, N=120, Recruiting, Sponsor: Hopital Foch
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Omnaris (ciclesonide nasal spray) / Covis Pharma, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Enrollment change: A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray (clinicaltrials.gov) - Jun 5, 2013
P4, N=0, Withdrawn, Sponsor: University of Chicago
Not yet recruiting --> Recruiting N=13 --> 0
- ||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion: Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone) (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=2000, Completed, Sponsor: GlaxoSmithKline
N=13 --> 0 Active, not recruiting --> Completed
- Venclexta (venetoclax) / Roche, AbbVie
Enrollment open: A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (clinicaltrials.gov) - Jun 5, 2013
P1, N=30, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Suspended --> Recruiting
- |||| clocortolone pivalate cream / Generic mfg.
Trial completion: Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis (clinicaltrials.gov) - Jun 4, 2013
P4, N=60, Completed, Sponsor: Promius Pharma, LLC
Suspended --> Recruiting Recruiting --> Completed
- || hydroxychloroquine / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial (clinicaltrials.gov) - Jun 3, 2013
P3, N=60, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
- prednisolone / Generic mfg., vincristine / Generic mfg.
Trial termination: Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas (clinicaltrials.gov) - Jun 3, 2013
P2, N=8, Terminated, Sponsor: Medical College of Wisconsin
Recruiting --> Completed Active, not recruiting --> Terminated; The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas
- Venclexta (venetoclax) / Roche, AbbVie
Enrollment open: BELLINI: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2013
P1, N=30, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Terminated; The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas Suspended --> Recruiting
- | morphine sulphate / Generic mfg.
New P4 trial, Combination therapy: Dexamethasone for Post Cesarean Delivery Analgesia (clinicaltrials.gov) - Jun 2, 2013
P4, N=52, Recruiting, Sponsor: University of Iowa
- Trial termination: Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant (clinicaltrials.gov) - Jun 2, 2013
P2, N=45, Terminated, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Active, not recruiting --> Terminated; The study was closed early due to weak accrual on June 26, 2012.
- ||| tabalumab (LY2127399) / Eli Lilly
Enrollment change, Combination therapy: A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) (clinicaltrials.gov) - Jun 2, 2013
P2, N=213, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Terminated; The study was closed early due to weak accrual on June 26, 2012. N=771 --> 213
- dexamethasone / Generic mfg.
Enrollment change, Surgery: Dexamethasone for Pain After Shoulder Surgery (clinicaltrials.gov) - Jun 2, 2013
P4, N=97, Completed, Sponsor: University of Aarhus
N=771 --> 213 N=75 --> 97
- ||||| abiraterone acetate / Generic mfg.
New P2 trial, Adverse events, Metastases: Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy (clinicaltrials.gov) - Jun 2, 2013
P2, N=144, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
- dexamethasone / Generic mfg.
Trial completion, Surgery: Dexamethasone for Pain After Shoulder Surgery (clinicaltrials.gov) - Jun 2, 2013
P4, N=97, Completed, Sponsor: University of Aarhus
N=75 --> 97 Recruiting --> Completed
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Trial completion, Metastases: A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies (clinicaltrials.gov) - Jun 2, 2013
P1, N=12, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Recruiting --> Completed
- sirexatamab (DKN-01) / Leap Therap
Enrollment open: A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 30, 2013
P1/2, N=20, Recruiting, Sponsor: Dekkun Corporation
Recruiting --> Completed Not yet recruiting --> Recruiting
- abiraterone acetate / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Metastases: A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer (clinicaltrials.gov) - May 30, 2013
P2, N=82, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial withdrawal: Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 29, 2013
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Completed --> Withdrawn
- Enrollment change: Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 29, 2013
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Completed --> Withdrawn N=100 --> 0
- Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Decadron (dexamethasone) / Merck (MSD), Metopirone (metyrapone) / HRA Pharma
Biomarker, Enrollment open: Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures (clinicaltrials.gov) - May 28, 2013
P4, N=350, Recruiting, Sponsor: University of Michigan
N=100 --> 0 Not yet recruiting --> Recruiting
- || Nasonex (mometasone furoate nasal spray) / Merck (MSD)
New P3 trial: MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC RHINITIS (EUDRACT) - May 27, 2013
P3, N=350, Ongoing, Sponsor: PH&T SpA
- ||| budesonide/formoterol / Generic mfg.
Trial completion: ENSURE: Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation (clinicaltrials.gov) - May 27, 2013
P=N/A, N=1500, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- fluocinonide / Generic mfg., tazarotene topical / Generic mfg., sorafenib / Generic mfg.
Trial termination: Sorafenib-induced Hand- Foot Skin Reaction Treatment (clinicaltrials.gov) - May 27, 2013
P2, N=6, Terminated, Sponsor: Northwestern University
Active, not recruiting --> Completed Completed --> Terminated; Study was halted due to poor subject accrual.
- fluocinonide / Generic mfg., tazarotene topical / Generic mfg., sorafenib / Generic mfg.
Enrollment change: Sorafenib-induced Hand- Foot Skin Reaction Treatment (clinicaltrials.gov) - May 27, 2013
P2, N=6, Terminated, Sponsor: Northwestern University
Completed --> Terminated; Study was halted due to poor subject accrual. N=120 --> 6
- || bortezomib / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Clinical: ENDURANCE: Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 27, 2013
P3, N=756, Recruiting, Sponsor: Eastern Cooperative Oncology Group
- ||||| Ninlaro (ixazomib) / Takeda
New P1/2 trial, Combination therapy: MC1382: Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis (clinicaltrials.gov) - May 27, 2013
P1/2, N=51, Recruiting, Sponsor: Mayo Clinic
- Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Trial suspension: Validation of the Rhinitis Control Scoring System (RCSS) (clinicaltrials.gov) - May 23, 2013
P=N/A, N=50, Suspended, Sponsor: Laval University
N=120 --> 6 Recruiting --> Suspended
- || Opdivo (nivolumab) / BMS
Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - May 23, 2013
P1, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Suspended Initiation date: Jan 2012 --> Aug 2012
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Combination therapy, Monotherapy: SERENE: A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 22, 2013
P3, N=511, Completed, Sponsor: Genentech
Initiation date: Jan 2012 --> Aug 2012 Active, not recruiting --> Completed
- || marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
Enrollment change, Metastases: Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies (clinicaltrials.gov) - May 22, 2013
P1, N=86, Completed, Sponsor: Triphase Research and Development I Corporation
Active, not recruiting --> Completed N=50 --> 86
- |||||||||| dexamethasone / Generic mfg.
New P3 trial: Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) (clinicaltrials.gov) - May 22, 2013
P3, N=480, Recruiting, Sponsor: Beijing Bozhiyin T&S Co., Ltd.
- | New P2 trial: Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) (clinicaltrials.gov) - May 22, 2013
P2, N=75, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- ||| marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
Trial completion, Metastases: Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies (clinicaltrials.gov) - May 22, 2013
P1, N=86, Completed, Sponsor: Triphase Research and Development I Corporation
N=50 --> 86 Active, not recruiting --> Completed
- ||||| thioguanine / Generic mfg.
Enrollment change: AALL0331: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 21, 2013
P3, N=5377, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=3381 --> 5377